Literature DB >> 8613950

Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria.

M D Salducci1, A M Chauvet-Monges, J P Tillement, E Albengres, B Testa, P Carrupt, A Crevat.   

Abstract

When applied to rat liver mitochondria in contact with Ca++, cyclosporine A (CsA) induced both an accumulation of this ion and a decrease in oxidative phosphorylation. Trimetazidine (TMZ) reversed both phenomena in a dose-dependent manner. These two effects were demonstrated in separate experiments. A decrease in oxidative phosphorylation was observed with succinate as substrate. V3 and P/O (ratio corresponds to the number of ADP molecules added in the medium per oxygen atom consumed during phosphorylation and represents the yield of ATP synthesis) were simultaneously decreased by CsA (1 microM) and restored by TMZ. Ca++ accumulation in mitochondria was observed when it was added to the mitochondrial suspension; its uptake was followed by a new equilibrium. CsA prolonged its duration, whereas TMZ reduced it in a dose-dependent manner. The same phenomenon was observed when ADP was used instead of CsA. Ca++ efflux from mitochondria could be induced by TMZ without the addition of CsA. It was immediate and always partial and followed by a reuptake process only observed at concentrations of TMZ of >1 microM. Compared with ruthenium red, which blocks Ca++ uniporter, TMZ seemed to act on Ca++ efflux mechanisms. Interestingly, low TMZ doses promote a Ca++ efflux process without activating reentry mechanism, which may explain the correction of deleterious effect of CsA on V3 and P/O. As nephrotoxicity observed in humans after CsA chronic administration is considered to be related, at least in part, to an alteration of Ca++ intracellular homeostasis, TMZ seems to be a candidate for alleviation of CsA nephrotoxic effects in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613950

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Protective effects of trimetazidine on bone marrow mesenchymal stem cells viability in an ex vivo model of hypoxia and in vivo model of locally myocardial ischemia.

Authors:  Hongxin Xu; Gangyan Zhu; Yihao Tian
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

2.  [(3)H]-trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance.

Authors:  D Morin; R Sapena; A Elimadi; B Testa; S Labidalle; A Le Ridant; J P Tillement
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

3.  The pH-partition profile of the anti-ischemic drug trimetazidine may explain its reduction of intracellular acidosis.

Authors:  F Reymond; G Steyaert; P A Carrupt; D Morin; J P Tillement; H H Girault; B Testa
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

4.  Anticonvulsant and antioxidant actions of trimetazidine in pentylenetetrazole-induced kindling model in mice.

Authors:  Seema Jain; Nidhi Bharal; Sonam Khurana; Pramod Kumari Mediratta; Krishna Kishore Sharma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-12       Impact factor: 3.000

5.  Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain.

Authors:  N Serkova; W Jacobsen; C U Niemann; L Litt; L Z Benet; D Leibfritz; U Christians
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 6.  A Potential Route to Reduce Ischemia/Reperfusion Injury in Organ Preservation.

Authors:  Marc Micó-Carnero; Mohamed Amine Zaouali; Carlos Rojano-Alfonso; Cristina Maroto-Serrat; Hassen Ben Abdennebi; Carmen Peralta
Journal:  Cells       Date:  2022-09-05       Impact factor: 7.666

7.  Effects of trimetazidine on mitochondrial respiratory function, biosynthesis, and fission/fusion in rats with acute myocardial ischemia.

Authors:  Wen Shi; Wenfeng Shangguan; Yue Zhang; Can Li; Guangping Li
Journal:  Anatol J Cardiol       Date:  2017-07-25       Impact factor: 1.596

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.